Kovitz Investment Group Partners LLC Boosts Stock Holdings in Cencora, Inc. $COR

Kovitz Investment Group Partners LLC lifted its position in Cencora, Inc. (NYSE:COR) by 728.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,067 shares of the company’s stock after purchasing an additional 29,955 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Cencora were worth $11,506,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in COR. Kemnay Advisory Services Inc. purchased a new position in Cencora in the fourth quarter valued at $25,000. Oakworth Capital Inc. purchased a new stake in shares of Cencora during the 4th quarter worth about $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora during the 4th quarter valued at about $27,000. Archer Investment Corp grew its position in shares of Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after acquiring an additional 47 shares during the period. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora in the 4th quarter valued at about $29,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Down 1.8%

COR opened at $271.99 on Friday. The company has a market cap of $52.92 billion, a PE ratio of 20.86, a price-to-earnings-growth ratio of 1.50 and a beta of 0.59. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The company has a 50-day moving average price of $285.65 and a 200 day moving average price of $324.72. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the previous year, the firm posted $4.42 earnings per share. The company’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a stock buyback plan on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s payout ratio is currently 18.40%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on COR. Evercore set a $360.00 price target on Cencora in a report on Wednesday, April 8th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. UBS Group boosted their price objective on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Wells Fargo & Company reduced their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research note on Monday, May 11th. Finally, William Blair assumed coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating on the stock. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.